Press Room

12th DPI China Technology Conference

Start
Thursday, March 27, 2025 - 09:00
End
Friday, March 28, 2025 - 18:00
Location: Nanjing, China
DPI China 2025

Looking for a complete One-Site Solution for your inhalation and nasal therapies? 
Meet Hovione at the 12th DPI China Technology Conference! 

Hovione offers customized high-performance APIs, particle engineering and formulation along with a full range of highly specialized, patented, and innovative devices, all in one site. 

Don’t miss the chance to speak with our Inhalation Experts in Nanjing. Our team is ready to share how this integration on a single site can support your project.

Session Title:
From Particle to Drug Delivery: Integrated Platforms for Respiratory Drug Products
March 28th, 2025
Session III, 11:30 -12:00

Speaker: 
João Pires, PhD - RD Senior Manager, Inhalation and Advanced Drug Delivery at Hovione

Description: This presentation covers the latest trends in pulmonary and nasal formulations and explores how Hovione’s integrated approach addresses the challenges in developing new therapeutics. From innovative formulation and device platforms to a unique set of expertise and capabilities, the session will guide the audience through the drug development cycle of dry powder formulations. It will highlight how an integrated strategy - encompassing formulation, process, and device optimization - can lead to better and more robust respiratory drug products.

Key learnings:

  • Discover the latest advancements in formulation, particle design, and device platforms that address the growing complexity of respiratory formulations and enable next-generation therapeutics
  • Learn how a seamless integration of formulation, process, and device in the drug development cycle can streamline development, reduce risks, and achieve better products

Delivering solutions every breath of the way.

We live and breathe innovation for the successful delivery of your inhalation and nasal therapies.

Schedule a meeting today.

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026